Transforming Cancer Diagnostics: Prof. Iris Barshack’s Pioneering Work at Sheba Medical Center

Reimagining Pathology Through Innovation

At the forefront of transformative healthcare innovation, Sheba Medical Center continues to redefine the boundaries of what’s possible in patient care. Leading this charge in the field of pathology is Prof. Iris Barshack, Director of Sheba’s Institute of Pathology and Chair of the Israeli Association of Pathologists. With nearly two decades at the helm of one of Israel’s most prestigious medical institutions, Prof. Barshack has pioneered an approach that seamlessly integrates cutting-edge technology with compassionate patient care.

Prof. Barshack’s vision extends beyond conventional pathology. After years of clinical practice, she began exploring how to reduce the necessity for invasive biopsies by predicting histological appearances through advanced imaging modalities. This groundbreaking approach aims to decrease the need for invasive procedures while simultaneously saving time and costs in the diagnostic process.

Digital Transformation in Pathology

Under Prof. Barshack’s leadership, Sheba’s Institute of Pathology has positioned itself as a global leader in digital pathology since completing its transition in 2019. This transformation has profoundly impacted both diagnostic capabilities and training methodologies, with all pathologists now having remote access to digital pathology workstations.

The implementation has enabled comprehensive image management, telepathology for remote consultations, enhanced education through case sharing, and advanced image analysis with AI algorithms for personalized medicine. These improvements have significantly enhanced laboratory efficiency, pathologist productivity, and diagnostic quality.

Beyond Sheba’s walls, Prof. Barshack envisions establishing a National Web of Pathology that would enable all pathologists in Israel to use a unified digital platform for both diagnosis and training.

Revolutionary AI Implementation for NSCLC

The most impressive achievement under Prof. Barshack’s leadership is Sheba’s implementation of AI solutions in the pathology workflow for non-small cell lung cancer (NSCLC).

“At the Institute of Pathology at Sheba, we are the only center in the world that has already implemented AI solutions in the workflow of pathologies,” Prof. Barshack states. “In cases of non-small cell lung cancer, immediately after scanning the slide and digital pathology image, we use algorithms – some developed in our own lab and others in collaboration with startup companies.”

The Rapid Digital-Molecular Diagnostic Service: From Weeks to Hours

The impact of this implementation has been transformative. The traditional diagnostic process for NSCLC typically requires comprehensive next-generation sequencing of 500+ genes, taking up to four weeks – precious time that critically ill patients simply don’t have. With Sheba’s integrated AI approach, the diagnostic timeline has been compressed from 4 weeks to just a few hours.

Sheba’s service integrates AI-based digital pathology methods developed with Imagene AI and molecular profiling on the Idylla Biocartis platform, creating a remarkable advancement in the diagnostic process:

Traditional Approach (4 weeks): After biopsy, tissue samples follow conventional biomarker testing through IHC/FISH and NGS methods, with final reports typically produced after four weeks.

Sheba’s AI-Powered Approach (Hours): AI software analyzes the whole slide image immediately after scanning, taking an average of just 4 minutes for initial biomarker inference. The system flags samples carrying critical biomarkers including EGFR mutations, MET ex14 skip, BRAF V600E, ERBB2 mutations, and various fusion alterations. Positive findings are verified via the Idylla Biocartis platform in just a few hours.

This dramatic reduction in diagnostic time has profound implications for patient care, enabling oncologists to initiate appropriate targeted therapies much sooner, potentially saving lives that might otherwise be lost during the traditional waiting period.

Strategic Collaboration with Roche

Building on these achievements, Sheba recently announced a strategic collaboration with Roche to further develop AI-powered digital pathology solutions for NSCLC. The partnership aims to integrate artificial intelligence algorithms with Roche’s navify® Digital Pathology platform to streamline molecular marker detection in NSCLC.

The initiative will leverage Sheba’s expertise in digital pathology alongside Roche’s clinical decision support capabilities to develop integrated algorithms that not only identify biomarkers but also predict treatment response patterns. While initially focused on NSCLC, the partners envision expanding these technological advances to other cancer types and diseases in the future.

Real Impact on Patient Lives

Behind the technological innovation lies a steadfast focus on patient outcomes. The real-world impact can be seen in individual success stories where rapid diagnosis led to life-saving treatment decisions.

In one notable case, a patient arrived at Sheba with metastatic lung cancer in what appeared to be an end-of-life situation. Through the rapid diagnostic pathway, clinicians were able to perform a quick biopsy, scan the slide directly, and use the AI algorithm to detect an EGFR mutation within hours. This allowed for immediate initiation of targeted therapy, resulting in a dramatic improvement in the patient’s condition.

These aren’t just isolated successes. The ability to provide actionable diagnostic information within hours rather than weeks is transforming the standard of care for NSCLC patients, many of whom cannot afford to wait for traditional diagnostic timelines.

The Future of Pathology: Beyond NSCLC

Looking ahead, the technologies being developed have the potential to transform diagnostic processes for multiple cancer types and other diseases. As these solutions continue to evolve, they can further reduce diagnostic timeframes, improve accuracy in biomarker detection, enable more personalized treatment approaches, and reduce healthcare costs through efficiency gains.

Through the visionary leadership of professionals like Prof. Iris Barshack, Sheba Medical Center continues to demonstrate that technological innovation and compassionate care can work together effectively, creating a future where diagnosis is faster, treatment is more precise, and more lives are saved.